Clinical and prognostic significance of cytokine receptor expression in adult acute lymphoblastic leukemia: Interleukin-2 receptor α-chain predicts a poor prognosis

Leukemia

Volumn 21, Issue 2, 2007, Pages 326-332

  Nakase, K ^a   Kita, K ^a,b   Miwa, H ^a,c   Nishii, K ^a   Shikami, M ^a,c   Tanaka, I ^d   Tsutani, H ^e   Ueda, T ^e   Nasu, K ^f   Kyo, T ^g   Dohy, H ^g   Shiku, H ^a   Katayama, N ^a  

^a MIE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Tokura Hospital   (Japan)

^c AICHI MEDICAL UNIVERSITY   (Japan)

^d Suzuka Kaisei Hospital   (Japan)

^e UNIVERSITY OF FUKUI   (Japan)

^f OSAKA RED CROSS HOSPITAL   (Japan)

^g ATOMIC BOMB SURVIVORS HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACLARUBICIN; ANTHRACYCLINE; ASPARAGINASE; CD135 ANTIGEN; CD33 ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; CYTARABINE DERIVATIVE; CYTOKINE RECEPTOR; DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 2 RECEPTOR BETA; INTERLEUKIN 3 RECEPTOR; INTERLEUKIN 4 RECEPTOR; INTERLEUKIN 5 RECEPTOR; INTERLEUKIN 6 RECEPTOR; INTERLEUKIN 7 RECEPTOR; INTERLEUKIN 7 RECEPTOR ALPHA; METHOTREXATE; MICROSOMAL AMINOPEPTIDASE; MITOXANTRONE; PREDNISOLONE; STEM CELL FACTOR RECEPTOR; UNINDEXED DRUG; VINCRISTINE; VINDESINE;

ACUTE LYMPHOCYTIC LEUKEMIA; ADULT; ARTICLE; B LYMPHOCYTE; CANCER SURVIVAL; CELL LINEAGE; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LEUKOCYTOSIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PHILADELPHIA 1 CHROMOSOME; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; T LYMPHOCYTE;

EID: 33846512834     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404497     Document Type: Article

References (39)

1. Oh H, Gale RP, Zhang MJ, Passweg JR, Ino T, Murakami H et al. Chemotherapy vs HLA-identical sibling bone marrow transcripts for adults with acute lymphoblastic leukemia in first remission. Bone Marrow Transplant 1998; 22: 253-257.
2. Ribera JM, Oriol A, Bethencourt C, Parody R, Hemendez-Rivas JM, Moreno MJ et al. Comparison of intensive chemotherapy, allogeneic or autologous stem cell transplantation as post remission treatments for adult patients with high-risk acute lymphoblastic leukemia. Results of the PETHEMA ALL-93 trial. Haematologica 2005; 90: 1346-1356.
3. Thomas X, Boiron J-M, Huguet F, Dombret H, Bradstock K, Vey N et al. Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol 2004; 20: 4075-4086.
4. Lowengerg B, Touw IP. Hematopoietic growth factors and their receptors in acute leukemia. Blood 1993; 81: 281-292.
5. Lotem J, Sachs L. Cytokine control of developmental programs in normal hematopoiesis and leukemia. Oncogene 2002; 21: 3284-3294.
6. Koubek K, Stary J, Kumberova A, Kamova H, Filipec M. Occurrence of cytokine receptors on different lymphoid leukaemia cells. Eur J Haematol 1999; 63: 1-10.
7. Wu S, Gessner R, von Stockelberg A, Kirchner R, Henze G, Seeger K. Cytokine/cytokine receptor gene expression in childhood acute lymphoblastic leukemia. Cancer 2005; 103: 1054-1063.
8. Sato N, Caux C, Kitamura T, Watanabe Y, Arai K, Banchereau J et al. Expression and factor-dependent modulation of the interleukin-3 receptor subunit on human hematopoietic cells. Blood 1993; 82: 752-761.
9. Watanabe Y, Kitamura T, Hayashida K, Miyajima A. Monoclonal antibody against the common β subunit (βc) of the human interleukin-3 (IL-3), IL-5, and granulocyte-macrophage colony-stimulating factor receptors shows upregulation of βc by IL-1 and tumor necrosis factor-α. Blood 1992; 80: 2215-2220.
10. + cells. J Immunol 1981; 126: 1393-1397.
11. Tsudo M, Kitamura F, Migasaka M. Characterization of the interleukin-2 receptor bchain using three distinct monoclonal antibodies. Proc Natl Acad Sci USA 1989; 86: 1982-1986.
12. Shikami M, Miwa H, Nishii K, Takahashi T, Shiku H, Tsutani H et al. Myeloid differentiation antigen and cytokine receptor expression on acute myelocytic leukaemia cells with t(16;21)(p11;q22): Frequent expression of CD56 and interleukin-2 receptor α-chain. Br J Haematol 1999; 105: 711-719.
13. Asou H, Tashiro S, Hamamoto K, Otsuji A, Kita K, Kamada N. Establishment of a human myeloid leukemia cell line (Kasumi-1) with 8;21 chromosomal translocation. Blood 1991; 77: 2031-2036.
14. Kobayashi T, Tobinai K, Shimoyama M, Mikuni C, Konda S, Kozuru M et al. Long-term follow-up results of adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma treated with short-term, alternating non-cross-resistant chemotherapy: Japan Clinical Oncology Group Study 8702. Jpn J Clin Oncol 1999; 29: 340-348.
15. Tanimoto M, Miyawaki S, Ino T, Kyo T, Sakamaki H, Naoe T et al. Response-oriented individualized induction therapy followed by intensive consolidation and maintenance for adult patients with acute lymphoblastic leukemia: The ALL-87 study of the Japan Adult Leukemia Study Group (JALSG). Int J Hematol 1998; 68: 421-429.
16. Ueda T, Miyawaki S, Asou N, Kuraishi Y, Hiraoka A, Kuriyama K et al. Response-oriented individualized induction therapy with six drugs followed by four courses of intensive consolidation. 1 year maintenance and intensification therapy: The ALL90 study of the Japan Adult Leukemia Study Group. Int J Hematol 1998; 68: 279-289.
17. Takeuchi J, Kyo T, Naito K, Sao H, Takahashi M, Miyawaki S et al. Induction therapy by frequent administration of doxorubicin with four other drugs, followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia: The JALSG-ALL93 study. Leukemia 2002; 16: 1259-1266.
18. Jinnai I, Takeuchi J, Adachi K, Hiraoka A, Kyo T, Fukushima T et al. Strategy for treating adult ALL using new JALSG protocols. Symposium Proceedings of JALSG 10-year Anniversary International Symposium 1999, pp 39-41.
19. Nakase K, Kita k, Otsuji A, Anazawa H, Hoshino K, Sekine T et al. Diagnostic and clinical importance of interleukin-2 receptor alpha-chain expression on non-T-cell acute leukaemia cells. Br J Haematol 1992; 80: 317-326.
20. de Totero D, Francia di Celle P, Cignetti A, Foa R. The IL-2 receptor complex: Expression and function on normal and leukemic B cells. Leukemia 1995; 9: 1425-1431.
21. Paietta E, Racevskis J, Neuberg D, Rowe JM, Goldstone AH, Wiernik PH. Expression of CD25 (interleukin-2 receptor α-chain) in adult acute lymphoblastic leukemia predicts for the presence of BCR/ABL fusion transcripts: Results of a preliminary laboratory analysis of ECOG/MRC intergroup study E2993. Leukemia 1997; 11: 1887-1890.
22. Foa R, Caretto P, Fierro MT, Bonferroni M, Cardona S, Guarini A et al. Interleukin 2 does not promote the in vitro and in vivo proliferation and growth of human acute leukaemia cells of myeloid and lymphoid origin. Br J Haematol 1990; 75: 34-40.
23. Nakase K, Kita K, Kageyama S, Tsuji K, Miyanishi E, Miwa H et al. Clinical importance of interleukin-2 receptor α-chain expression in acute leukemia. Cancer Detect Prev 1997; 21: 273-279.
24. Moon Y, Kim Y, Kim K, Lim J, Kang CS, Kim WI et al. Plasma soluble interleukin-2 receptor (sIL-2R) levels in patients with acute leukemia. Ann Clin Lab Sci 2004; 34: 410-415.
25. Rubin LA, Jay G, Nelson DL. The released interleukin-2 receptor binds interleukin-2 efficiently. J Immunol 1986; 137: 3841-3844.
26. Pui C-H, Ip SH, Iflah S, Behm FG, Grose BH, Dodge RK et al. Serum interleukin-2 receptor levels in childhood acute lymphoblastic leukemia. Blood 1988; 71: 1135-1137.
27. Zoru U, Dallmann I, Grosse J, Kirchner H, Poliwoda H, Atzpodien J. Soluble interleukin 2 receptors abrogate IL-2 induced activation of peripheral mononuclear cells. Cytokine 1994; 6: 358-364.
28. Paietta E, Nelson DL, Andersen J, Dutcher JP, Wiernik PH. Levels of soluble interleukin-2 receptors are predictive of response in patients with interleukin-2 and lymphokine-activated killer cells. Med Oncol 1995; 12: 121-124.
29. Testa U, Riccioni R, Militi S, Coccia E, Stellacci E, Samoggia P et al. Elevated expression of IL-3Rα in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis. Blood 2002; 100: 2980-2988.
30. Tsuura Y, Suzuki T, Honma K, Sano M. Expression of c-kit ptotein in proliferative lesions of human breast: Sexual difference and close association with phosphotyrosine status. J Cancer Res Clin Oncol 2002; 128: 239-246.
31. Nishii K, Kita K, Miwa H, Kawakami K, Nakase K, Masuya M et al. c-kit gene expression in CD7-positive acute lymphoblastc leukemia: Close correlation with expression of myeloid-associated antigen CD13. Leukemia 1992; 6: 662-668.
32. Carow CE, Levenstein M, Kaufmann SH, Chen J, Amin S, Rockwell P et al. Expression of the hematopoietic growth factor receptor FLT3 (STK-1/Flk2) in human leukemias. Blood 1996; 87: 1089-1096.
33. Drexler HG. Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells. Leukemia 1996; 10: 588-599.
34. Kiyoi H, Naoe T, Nakano Y, Yokota S, Minami S, Miyawaki S et al. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood 1999; 93: 3074-3080.
35. Frohling S, Schlenk RF, Breitruck J, Benner A, Kreitmeler S, Tobis K et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: A study of the AML study group Ulm. Blood 2002; 100: 4372-4380.
36. Ozeki K, Kiyoi H, Hirose Y, Iwai M, Ninomiya M, Kodera Y et al. Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemia. Blood 2004; 103: 1901-1908.
37. Yanada M, Takeuchi J, Sugiura I, Akiyama H, Usui N, Yagasaki F et al. High complete remission rate and promising outcome by combination of Imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: A phase I study by the Japan adult leukemia study group. J Clin Oncol 2006; 24: 460-466.
38. Waldmann TA, White JD, Carrasquillo JA, Raynolds JC, Paik CH, Gansow OA et al. Radioimmunotherapy of interleukin-2r α-expressing adult T-cell leukemia with Yttrium-90-labeled anti-Tac. Blood 1995; 86: 4063-4075.
39. Koon HB, Severy P, Hagg DS, Butler K, Hill T, Jones AG et al. Antileukemic effect of daclizumab in CD25 high-expressing leukemias and impact of tumor burden on antibody dosing. Leuk Res 2006; 30: 190-203.